PhytoTech Medical Ltd (ASX:PYL) are pleased to provide an investor presentation titled 'From Farm to Pharma - Unlocking the Medical Cannabis Value Chain'; a science-driven, global approach focused on the medicinal potential of Cannabis and its derivatives.
PhytoTech Medical Ltd (ASX:PYL) is pleased to announce that Satipharm AG ("Satipharm"), a 100% controlled entity of MMJ Bioscience Limited ("MMJ"), has signed an agreement with AI FAME GmbH ("AI FAME") to market and distribute its Medical Cannabis products globally.
PhytoTech Medical Limited (ASX:PYL) (the "Company") is pleased to provide an update on the progress of its oral drug development. On the 11 June 2015 the Company submitted two formal clinical documents, which, when approved, will allow it to begin its Phase 1 study of its two pro-nano-lipospheres Tetrahyrocannabidiol (THC) and Cannabidiol (CBD) formulations.
PhytoTech Medical Limited (ASX:PYL) is pleased to announce that the conditions precedent to the merger transaction with MMJ Bioscience Inc have been satisfied or waived and accordingly the transaction is now unconditional.
PhytoTech Medical Limited (ASX:PYL) today advises that the newly designed corporate website is now live and available at http://www.phytotechmed.com.
PhytoTech Medical Limited (ASX:PYL) ("PYL" or the "Company") is pleased to announce that production of MMJ Bioscience Limited's ("MMJ") proprietary, Good Manufacturing Practice ("GMP") produced cannabidiol ("CBD") capsules commenced in Switzerland on 25 May 2015.
PhytoTech Medical Limited (ASX:PYL) is pleased to provide an update on the proposed merger with MMJ Bioscience Inc ("MMJ").
